Endometriotic lesions are associated with hormonal imbalance, including increased estrogen synthesis, metabolism and progesterone resistance. These hormonal changes cause increased proliferation, inflammation, pain and infertility. Hormonal imbalances are targets for treatment. Therapeutic strategies and innovations of hormonal drugs for endometriosis are increasing. Acting on estrogen receptors are hormonal drugs decreasing systemic and local estrogen synthesis (GnRH analogs, GnRH antagonists, Aromatase inhibitors) or estrogen activity (selective estrogen receptor modulators). The progesterone resistance is counteracted by progestins (Medroxyprogesterone acetate, Dienogest, Danazol, Levonorgestrel) or by Selective progesterone receptor modulators, a class of drugs under development. The future trend will be to define new drugs to use for prolonged period of time and with poor side effects considering endometriosis a chronic disease.

Tosti, C., Biscione, A., Morgante, G., Bifulco, G., Luisi, S., Petraglia, F. (2017). Hormonal therapy for endometriosis: from molecular research to bedside. EUROPEAN JOURNAL OF OBSTETRICS, GYNECOLOGY, AND REPRODUCTIVE BIOLOGY, 209, 61-66 [10.1016/j.ejogrb.2016.05.032].

Hormonal therapy for endometriosis: from molecular research to bedside

Tosti, Claudia;Biscione, Antonella;Morgante, Giuseppe;Luisi, Stefano;
2017-01-01

Abstract

Endometriotic lesions are associated with hormonal imbalance, including increased estrogen synthesis, metabolism and progesterone resistance. These hormonal changes cause increased proliferation, inflammation, pain and infertility. Hormonal imbalances are targets for treatment. Therapeutic strategies and innovations of hormonal drugs for endometriosis are increasing. Acting on estrogen receptors are hormonal drugs decreasing systemic and local estrogen synthesis (GnRH analogs, GnRH antagonists, Aromatase inhibitors) or estrogen activity (selective estrogen receptor modulators). The progesterone resistance is counteracted by progestins (Medroxyprogesterone acetate, Dienogest, Danazol, Levonorgestrel) or by Selective progesterone receptor modulators, a class of drugs under development. The future trend will be to define new drugs to use for prolonged period of time and with poor side effects considering endometriosis a chronic disease.
2017
Tosti, C., Biscione, A., Morgante, G., Bifulco, G., Luisi, S., Petraglia, F. (2017). Hormonal therapy for endometriosis: from molecular research to bedside. EUROPEAN JOURNAL OF OBSTETRICS, GYNECOLOGY, AND REPRODUCTIVE BIOLOGY, 209, 61-66 [10.1016/j.ejogrb.2016.05.032].
File in questo prodotto:
File Dimensione Formato  
Hormonal-therapy-for-endometriosis-2017.pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 464.27 kB
Formato Adobe PDF
464.27 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
postprintmorgante998396.pdf

accesso aperto

Tipologia: Post-print
Licenza: Creative commons
Dimensione 866.6 kB
Formato Adobe PDF
866.6 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/998396